Sidhartha Sinha, MD, is an assistant professor of gastroenterology and hepatology at Stanford University.

When Medications Fall Short: Exploring Diet in Mild Crohn’s Disease, With Sidhartha Sinha, MD

For patients with mild Crohn’s disease (CD), treatment decisions are often complicated by a lack of appropriate therapeutic options. While corticosteroids, the onlyUS Food and Drug Administration (FDA)-approved therapy for this population, can rapidly improve symptoms, their long-term toxicity often outweighs their benefits. As a result, there has been a growing interest in nonpharmacologic strategies for disease management.

“We often think about [steroids] as being some of the best drugs and some of the worst drugs at the same time. They can make patients feel better, and sometimes we need to do that and do that quickly, but they come with a whole slew of side effects,” Sidhartha Sinha, MD, an assistant professor of gastroenterology and hepatology at Stanford, told HCPLive. “We're always looking at ways to improve the treatment of patients, and fortunately, now we have many advanced therapies that offer some benefit, but patients who have mild and sometimes very moderate Crohn's disease fit into this area where there may not be therapies that are appropriate for them. In these cases, we think that lifestyle can really make an impact.”

With this therapeutic gap in mind, he and a team of investigators conducted an open-label, randomized, controlled, clinical trial assessing the effectiveness of a fasting-mimicking diet (FMD) for reducing clinical disease activity in patients with mild-to-moderate CD. In the study, patients consumed a FMD for 5 consecutive days per month for 3 consecutive months. For the remaining days in each month, patients consumed their regular baseline diet. Patients in the control group continued their baseline diet.

Study results showed that short, structured periods of significant caloric restriction were associated with improvements in clinical disease activity and biochemical markers of inflammation. In some cases, patients achieved complete clinical remission.

However, Sinha emphasized that FMD should not be viewed as a replacement for standard medical therapy. Instead, he says the results suggest that diet may serve as a complementary strategy, especially for patients who fall into the gray zone between minimal symptoms and disease severe enough to justify immunosuppressive or biologic treatment.

One of the notable strengths of the study was its real-world design. Participants reflected everyday clinical practice, including patients already receiving pharmacologic therapy as well as those who had chosen not to initiate medication. Across both groups, the dietary intervention was associated with reductions in disease burden, reinforcing the idea that nutritional strategies may exert benefits independent of medication status.

Sinha went on to emphasize the importance of considering safety, noting that an intervention should never cause harm. Accordingly, his study only enrolled patients with mild to moderate disease and excluded those who were pregnant, underweight, or otherwise at risk.

He noted that despite the low caloric intake during the fasting periods, no significant differences in weight were observed between the intervention and control groups, likely due to post-intervention caloric rebound. Adverse effects such as fatigue and headache were mild, transient, and resolved quickly once normal eating resumed, something Sinha says can likely be expected after long periods of not eating much food or skipping meals.

Taken together, he says the findings suggest that carefully designed dietary interventions like FMD may offer a promising, low-risk adjunct for patients with mild Crohn’s disease while also opening the door to more mechanistically informed lifestyle research in IBD.

Editors’ note: Sinha reports no relevant disclosures.

Brooks A. Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease. HCPLive. January 13, 2026. Accessed January 16, 2026. 

https://www.hcplive.com/view/fasting-mimicking-diet-elicits-clinical-biochemical-response-in-mild-crohn-s-disease

Ha C. Management of Patients With Mild Crohn's Disease. 

https://pmc.ncbi.nlm.nih.gov/articles/PMC11346010/

Videos

Sinha explains current unmet needs in mild Crohn’s, the shortcomings of steroids for these patients, and what benefits a fasting-mimicking diet may offer.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

New data from the SCREAM project highlight a simple, low-cost strategy which may enable earlier detection and primary prevention of

 by investigators from Karolinska Institutet and are accompanied by a newly developed, web-based clinical tool utilizing age- and sex-specific estimated glomerular filtration rate (eGFR) percentiles.

In the absence of systematic screening programs, CKD is often diagnosed late in its course, typically after patients cross fixed diagnostic thresholds, most commonly defined as falling to an eGFR <60 mL/min/1.73 m². By this point, more than >50% of kidney function may already be lost. Although urine albumin testing can detect kidney damage earlier, it remains underutilized in routine practice, leaving creatinine-based eGFR reporting as the primary driver of CKD detection.

“This creates a passive approach to care, where action is delayed until kidney damage is already substantial,” Juan Jesús Carrero, MD, PhD, professor of epidemiology at Karolinska Institutet and senior author of the study, said in a statement. “In practice, we often wait until eGFR falls below 60, even though a large amount of kidney function has already been lost by then.”

To address this gap, Carrero and colleagues applied growth charts, a concept often used in pediatrics, to kidney function. Using nearly 7 million eGFR measurements collected between 2006 and 2021, the investigators constructed age- and sex-specific population distributions for eGFR and examined whether deviations from the population median eGFR were associated with adverse outcomes.

The SCREAM project included 1.1 million adults aged 40 to 100 years, representing approximately 80% of the population of Stockholm, Sweden.

Upon analysis, investigators found only about 25% of individuals with eGFR values > 60 mL/min/1.73 m² but < the 25th percentile had undergone additional urine albumin testing, underscoring missed opportunities for early evaluation and prevention.

Among individuals with eGFR values ≥ 60 mL/min/1.73 m², those with values < the 25th percentile for their age and sex had a significantly increased risk of kidney failure requiring dialysis or transplantation. They observed mortality followed a U-shaped pattern, with increased risk observed at both low and high extremes of the eGFR distribution.

For example, investigators explained the case of a 55-year-old woman with an eGFR of 80 mL/min/1.73 m². In clinical practice, she would typically be considered to have normal kidney function. However, in the study’s age- and sex-specific charts, this value corresponds to approximately the 10th percentile and was associated with a 3-fold higher risk of future dialysis initiation.

To support clinical implementation, the researchers made the eGFR distribution charts publicly available and developed a web-based calculator, allowing healthcare professionals to view a patient’s eGFR percentile relative to age- and sex-matched population norms.

“This approach is low-cost and easy to implement. When a creatinine test is ordered, clinicians could automatically receive not only the eGFR value but also its percentile for age and sex,” concluded Carrero. This would provide a simple way to identify patients who appear “normal” but are already deviating from expected kidney function and may benefit from earlier evaluation and prevention efforts.”

Simple method can enable early detection and prevention of chronic kidney disease. EurekAlert! Published January 16, 2026. Accessed January 16, 2026. 

https://www.eurekalert.org/news-releases/1112495

National Kidney Foundation. Estimated Glomerular Filtration Rate (eGFR). National Kidney Foundation. Published July 13, 2022. 

https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr

Articles

The SCREAM project introduces a cost-effective strategy for early detection and prevention of chronic kidney disease (CKD) using age- and sex-specific eGFR percentiles. Traditional CKD diagnosis often occurs late, after significant kidney function loss. The study applied pediatric growth chart concepts to eGFR data, revealing that individuals with eGFR values below the 25th percentile face increased risks of kidney failure. A web-based tool was developed to help clinicians assess eGFR percentiles, facilitating earlier intervention. This approach aims to identify patients at risk before substantial kidney damage occurs.

A population-based analysis suggests age and sex specific eGFR percentiles and a web-based calculator can identify CKD risk before diagnostic thresholds. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Age, Sex Specific eGFR Percentiles May Enable Earlier CKD Detection

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Appropriate escalation of treatment improves 

 control, new data suggest, and many patients living with poorly controlled CSU are not provided with guideline-recommended treatment escalation.

This was the conclusion of a recent analysis looking at CSU treatment patterns and unmet needs within real-world practice settings. Pavel Kolkhir, MD, from the Institute of Allergology, Charité – Universitätsmedizin Berlin in Germany, led a team of other investigators in the authoring of this analysis.

Kolkhir et al highlighted the hives and angioedema associated with CSU, noting the condition is estimated to impact about 0.5%–1.4% of the global population.

 CSU is also a disease with a substantial impact on patients’ quality of life.

“The objective of this analysis was to describe real-world treatment patterns and identify unmet needs, with particular focus on treatment escalation, the clinical outcome, and the response to treatment changes in patients with CSU prospectively collected through the chronic urticaria registry (CURE) from baseline (BL) to 6-month follow-up (FU),” Kolkhir and colleagues wrote.

In their study, Kolkhir and coauthors used CURE, an investigator-led, prospective, multinational observational disease registry. CURE is used across 79 sites across the world, representing the first global registry designed for advancing the world’s understanding of chronic urticaria and urticarial vasculitis via the systematic characterization of disease trajectory and outcomes. Additionally, CURE characterizes overall burden, associated comorbidities, varying therapeutic approaches and responses, and patterns of health care utilization.

For their current analysis, data were gathered through the CURE registry between December 2015 - April 2023 using standardized physician- and/or patient-completed questionnaires, as previously reported. Looking at adult participants with confirmed CSU diagnoses, the analysis was aimed at assessing treatment patterns at baseline and at a 6-month follow-up visit. Data deemed eligible for the study were drawn from 28 countries across Asia, Europe, Africa, and Latin and South America.

Effectiveness of patients’ treatments was assessed by looking at any shifts in the Urticaria Control Test scores between the point of baseline and 6 months. The definition used by Kolkhir and colleagues for complete treatment response was attainment of a UCT score of 16 along with an improvement of 3 points at minimum from the point of baseline. At baseline, evaluable information were available for 3995 individuals living with CSU. There were 1288 who had assessable UCT scores at follow-up.

Among patients who underwent treatment escalation between baseline and follow-up appointments, variation in complete response rates was by treatment step. Kolkhir and coauthors specifically highlighted 5.3% of subjects who changed from zero treatment to licensed-dose second-generation H1 antihistamines attained a complete response. This also took place among 6.0% of those escalated from licensed-dose to up-dosed second-generation H1 antihistamines.

A substantially greater proportion (28.4%) of patients who escalated from any dose of second-generation H1 antihistamines to omalizumab, by contrast, achieved complete disease control. In their multivariable analysis, the investigative team identified several factors linked to a diminished likelihood of treatment escalation at the point of follow-up. Specifically, those showing a baseline UCT score of 12 or greater and those already on omalizumab at baseline were noted to be significantly less likely to have their therapy escalated. Both associations reaching high statistical significance (

Notably, Kolkhir et al found among patients who met clinical criteria for escalation at baseline, 28.6% did not report appropriate treatment intensification. Among those within this subgroup, 18.0% remained on the same medication. At the same time, 10.6% were actually stepped down, and all continued to have inadequate disease control by their follow-up appointments.

In looking at the lack of escalation, various characteristics were shown to be associated with this lack of change among individuals with poorly-controlled disease. Shorter CSU duration (

 = .071) and the existence of both wheals and angioedema were linked with a lower likelihood of stepping up therapy (

 = .014). Additionally, the investigators found better baseline quality of life scores showed a correlation with non-escalation (

 = 0.001) along with ongoing treatment with up-dosed second-generation H1 antihistamines (

“The lack of guideline-recommended treatment escalation in patients with poorly controlled CSU highlights an important gap between evidence-based recommendations and actual clinical practice—a point that deserves further investigation,” Kolkhir and coauthors wrote.

Kolkhir P, Salameh P, Weller K, et al. Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry. Allergy. 2026 Jan 14. 

Maurer M, Weller K, Zuberbier T, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011 Mar;66(3):317-30. doi: 10.1111/j.1398-9995.2010.02496.x. Epub 2010 Nov 17. PMID: 21083565.

Recent data indicate that appropriate treatment escalation significantly improves control of chronic spontaneous urticaria (CSU), yet many patients do not receive guideline-recommended escalation. An analysis led by Pavel Kolkhir, MD, utilized the CURE registry to assess real-world treatment patterns and unmet needs in CSU management. Findings revealed that treatment escalation, particularly to omalizumab, resulted in higher complete response rates. However, a substantial proportion of patients did not receive necessary treatment intensification, highlighting a gap between clinical practice and evidence-based guidelines.

This study analyzed the Chronic Urticaria Registry (CURE), evaluating CSU treatment patterns and looking into unmet needs in real-world practice.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Final reflections from physicians Stein Gold, Soung, and Cotter, emphasizing multidisciplinary, patient-focused advances in psoriasis and PsA care.

Closing Thoughts on the Impact of IL-23s in Psoriasis and Psoriatic Arthritis

, despite the expanding therapeutic landscape. Linda Stein Gold, MD, and her colleagues analyze patient- and provider-reported data from the 

 surveys, revealing that many patients remain dissatisfied with current therapies and that oral agents are overwhelmingly preferred over injectables. The experts discuss how patient lifestyle, comorbidities, and psychosocial burden influence shared decision-making and treatment adherence. They also interpret the 

International Psoriasis Council’s (IPC)

 and explore its implications for reducing “topical churn” and advancing systemic therapy earlier in the disease course.

 and its potential to close current gaps in care. The panel provides an in-depth review of the 

 clinical development program, summarizing the 

 trials, which demonstrated superior efficacy versus deucravacitinib at both 16 and 24 weeks, with favorable safety and tolerability. They also discuss new 

 showing sustained clearance and no new safety signals in adults and adolescents. The faculty reflect on ICO’s implications for adolescent psoriasis and how early, aggressive oral intervention may help prevent progression to psoriatic arthritis, marking a significant milestone in the evolution of oral IL-23–targeted therapy.

The final portion of the series shifts focus to 

managing active psoriatic arthritis (PsA)

. The experts discuss new findings from the 

 demonstrated the first clear evidence of IL-23–mediated inhibition of structural joint damage, reinforcing the rationale for early biologic use in high-risk patients. They compare APEX to prior IL-23 studies, discuss implications for therapy sequencing, and highlight other emerging data from 

 studies. In closing, Stein Gold and colleagues emphasize a forward-looking approach that integrates personalized therapy selection, early detection of PsA, and cross-specialty collaboration to elevate standards of psoriasis care

Video Series

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 may offer a safer starting point for oral immunotherapy in egg-allergic patients, according to new data showing reduced IgE binding and blunted basophil activation.

“Heat-denaturation has long been considered a method to reduce allergen IgE binding and therefore make them less likely to trigger severe allergic responses,” wrote study investigator Marta Paolucci, PhD, from the University of Zurich, and colleagues.

 “Indeed, approximately 75% of children with milk or egg allergy tolerate heated or baked milk and egg products, suggesting that heating can modify protein structures and thereby alter the allergenicity of allergens. Our findings reinforce this concept, showing that heat-induced structural changes in these allergens can significantly reduce their ability to bind to IgE and can have a functional consequence on basophil activation.”

Oral immunotherapy is an emerging strategy for IgE-mediated food allergies, yet safety concerns, particularly systemic reactions during dose escalation, have limited widespread adoption. Due to potential reactions, dietary avoidance remains the primary management for food allergies.

Investigators assessed whether heat-induced structural changes in the major egg allergens, Gal d 1 and Gal d 2, could reduce their immunogenicity. 1By examining basophil activation in a cohort of 42 egg-allergic patients, the team examined whether heat-denatured allergens could serve as a safer alternative to native proteins in OIT protocols.

Participants were recruited from 3 centers in Switzerland: Children's Hospital Zurich (KISPI), Kantonsspital Baden (KSB), and University Hospital Zurich (USZ). Children were included if they had an allergist-confirmed oral or systemic reactivity to egg-containing foods based on a consistent clinical history of reactions to cooked, baked, scrambled, or raw egg. Adults were included if they had a documented history of reactions to egg-containing foods and a positive skin prick test.

Investigators obtained peripheral blood samples, determined patients’ sensitization status, and isolated and incubated basophils with native or heat-denatured egg allergen preparations. The team assessed basophil activation by measuring leukotriene release as a marker of degranulation.

Egg proteins were heat-denatured by diluting purified Gal d 1 (ovomucoid, LoTox natural Gal d 1, LTN-GD1-1, InBio, Charlottesville) and natural Gal d 2 (ovalbumin, LoTox natural Gal d 2, LTN-GD2-1, InBio) to 1 mg/mL in 1.5 mL Eppendorf tubes. Samples were heated at 20°C–100°C for 10 minutes to 6 hours using a water bath or thermo-shaker, then chilled in an ice bath for 1 minute to halt denaturation. Both heat-denatured and native controls were stored at 4°C until use in the study.

The study exposed Gal d 1 and Gal d 2 to heat treatments of varying temperature and duration, confirming structural alterations via SDS-PAGE, ELISA, NanoDSF, and circular dichroism. Functional assays showed that heat-denatured allergens triggered significantly lower basophil degranulation than their native counterparts, though individual responses varied with patients’ IgE sensitization profiles.

The analysis also demonstrated that heat-denaturation reduced IgE binding across the cohort, with time- and temperature-dependent effects on allergen structure. Among patients who still reacted to heat-denatured allergens, baseline egg-white IgE levels were greater, yet these patients required increased allergen doses to elicit leukotriene release. Overall, greater doses of heat-denatured allergens were necessary to trigger basophil activation compared with native allergens, indicating a measurable decrease in allergenic potency.

These results provide a mechanistic explanation for the lower allergenicity of baked or heat-processed eggs and support their potential integration into OIT regimens. Heat-denatured allergens could allow clinicians to initiate therapy with reduced risk of systemic reactions, particularly in patients with moderate IgE sensitization, while enabling dose escalation under controlled conditions.

The reduced basophil activation and IgE binding highlight the potential for safer, stepwise desensitization protocols. Investigators noted that future clinical trials are warranted to translate these molecular findings into practical OIT guidelines.

“Our findings contribute to the understanding of how thermal processing reduces allergenicity, supporting the development of safer food products and informing dietary management strategies for patients with egg allergy,” investigators wrote. “The work is highly relevant to clinicians, allergists, and food scientists as it bridges molecular allergology and practical implications for allergy diagnosis, food manufacturing, and immunotherapy approaches.”

Paolucci M, Breiding M, Dietrich M, et al. Heat-treated egg allergens show lower basophil activation: A path toward safer oral immunotherapy. 

. 2026;37(1):e70275. doi:10.1111/pai.70275

Muraro A, de Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. 

. 2022;15(9):100687. Published 2022 Sep 7. doi:10.1016/j.waojou.2022.100687

Heat-denatured egg allergens may offer a safer approach for oral immunotherapy in egg-allergic patients by reducing IgE binding and basophil activation. Approximately 75% of children with milk or egg allergies tolerate heated products, suggesting that heating alters protein structures and allergenicity. The study assessed heat-induced changes in egg allergens Gal d 1 and Gal d 2, showing reduced immunogenicity and allergenic potency. These findings support integrating heat-denatured allergens into oral immunotherapy regimens, potentially reducing systemic reactions and enabling controlled dose escalation, particularly in patients with moderate IgE sensitization.

Reduced IgE binding and blunted basophil activation in response to Gal d 1 and Gal d 2 suggest that heat-treated egg proteins could improve the safety of OIT for egg-allergic patients.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Heat-Denatured Egg Allergens May Offer Safer Oral Immunotherapy

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A cohort study of patients from the Women’s Health Study has highlighted the direct correlation between lipoprotein(a) levels and cardiovascular risk in healthy patients.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Very High Lipoprotein(a) Levels Linked to Cardiovascular Disease Among Healthy Women

A smartphone-based patient-caregiver educational program was evaluated in its impact on relapse rates in children with moderate-to-severe atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Digital Eczema Education Decreases Relapse Rates in Children in the Short-Term

Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.

FDA News

FDA Approves Oral Berotralstat for Pediatric HAE, With Jolanta Bernatoniene, PhD

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Lee describes misconceptions about ALD, the importance of multidisciplinary care, and what the future of pharmacotherapy for this disease may hold.

Hepatology

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

New sequence analysis suggests racial and ethnic disparities in KRT are pronounced in younger adults, affecting mortality, transplantation, and dialysis modality use.

Younger Adults Face Pronounced Racial, Ethnic Gaps in Kidney Therapy

Guy Young, MD, is the director of the Hemostasis and Thrombosis program at Children’s Hospital Los Angeles and professor of pediatrics at Keck School of Medicine of USC.

The SWITCH phase 1 trial aims to determine the optimal time to switch medications to minimize thrombotic risk and avoid leaving patients untreated.

Hematology

Ongoing Trial Investigates Switching from Emicizumab to Fitusiran in Hemophilia A, With Guy Young, MD

The Mortality Estimation in Renal Disease (MERD) score may help identify transplant candidates at highest risk of waitlist mortality.


New MERD Risk Score Predicts Mortality for Kidney Transplant Waitlist Patients

Ritlecitinib was evaluated for the treatment of non-segmental vitiligo (NSV) in different subgroups, stratified by demographics as well as various clinical characteristics.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

Clinical Experience with Tocilizumab and Upadacitinib in GCA Treatment 

Post-hoc analysis of the FLAME trial shows treatment discontinuation in COPD is associated with transient withdrawal effects and increased exacerbation risk.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Latest News

When Medications Fall Short: Exploring Diet in Mild Crohn’s Disease, With Sidhartha Sinha, MD

Age, Sex Specific eGFR Percentiles May Enable Earlier CKD Detection

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Closing Thoughts on the Impact of IL-23s in Psoriasis and Psoriatic Arthritis

Heat-Denatured Egg Allergens May Offer Safer Oral Immunotherapy